



Andrew D. Ruskin

Partner

Washington
+1.202.778.9415

Andrew.ruskin@klgates.com

OVERVIEW

Andrew Ruskin is a partner in the firm's Washington, D.C. office. He is a member of the health care and FDA practice group.

PROFESSIONAL BACKGROUND

Prior to joining the firm, Andrew counseled hospitals, pharmaceutical and medical device companies, and Medicare Advantage plans on a range of Medicare and Medicaid regulatory, litigation, and transactional matters. He advised on strategic issues surrounding coverage, reimbursement, and compliance, as well as drug pricing and price reporting. He defended clients in investigations by the U.S. Attorney's Office and the Department of Health and Human Services Office of Inspector General. He has also appeared before several regulatory tribunals, such as the Provider Reimbursement Review Board and the HCPCS Committee.

SPEAKING ENGAGEMENTS

- "Medicare Part B Drug Pricing," *American Conference Institute*, 17 November 2020
- "Price Transparency Rule Compliance, Informing the Patient, and Protecting the Hospital's Commercial Interests: Mutually Exclusive Concepts?" *AHLA Physicians and Hospitals Law Institute*, 10-11 February 2020
- "Limits on Agency Action by the Department of Health and Human Services: Impact on Providers in 2020 and Beyond," *American Health Law Association*
- "Provider-Based Status, Under Arrangements, Enrollment, and Related Medicare Requirements," *AHLA Institute on Medicare and Medicaid Payment Issues*, 20-22 March 2019
- "Provider-Based Status, Under Arrangements, Enrollment, and Related Medicare Requirements," *AHLA Institute on Medicare and Medicaid Payment Issues*, 21-23 March 2018
- "60-Day Repayment Rule: Implications for Internal and External Audits," *AHLA Annual Meeting*, June 2018
- "What's the Future of the CMS 60-Day Repayment Rule?" *AHLA Physicians and Hospitals Law Institute*, February 2018

- "Don't put the CAR-T before the Horse: Proper Planning for Novel Gene Therapies in an Uncertain Regulatory Environment"
- "Provider-Based Status under Siege: Do the Benefits Justify the Costs of Compliance?" *Fraud and Compliance Forum*, October 2017
- "Hospital-Based Status Post BBA Section 603: Is Expansion Still Possible?" *AHLA Annual Meeting*, June 2017
- "Provider-Based Status: What a Long, Strange Trip It's Been!" *AHLA Institute on Medicare and Medicaid Payment Issues*, 23-31 March 2017
- "What Every AMC Needs to Know About the 340B Program," *AHLA Legal Issues Affecting Academic Medical Centers and Other Teaching Institutions*, 9-10 March 2017
- "Medicare Part B: Drug Pricing, RX Drug Pricing Master Course," *American Conference Institute*, 1-2 November 2016

EDUCATION

- J.D., Case Western Reserve University School of Law, 1996
- A.B., Wesleyan University, 1987

ADMISSIONS

- Bar of District of Columbia
- Bar of New York

THOUGHT LEADERSHIP POWERED BY HUB

- 16 October 2020, 340B Update: Ryan White Clinics Sue in Response to Contract Pharmacy Actions as Congress Requests Information on Ways to Improve the 340B Program (*Alerts/Updates*)
- 28 September 2020, K&L Gates Reimbursement Corner: CMS's Proposed Phase-Out of the Inpatient Only List is Not Entirely Welcome News (*Alerts/Updates*)
- 25 September 2020, 340B Update: Congress and the Administration Respond to Drug Manufacturers' 340B Contract Pharmacy Actions (*Alerts/Updates*)
- 13 August 2020, K&L Gates Triage: 340B Update: Appellate Court Upholds 340B Payment Reduction as CMS Proposes Further Reductions for 2021 (*Podcast*)
- 5 August 2020, 340B Update: Appeals Court Upholds 340B Payment Reduction Under the OPPI as CMS Proposes Further Reductions for CY 2021 (*Alerts/Updates*)

- 30 July 2020, Appellate Court's Reversal in AHA v. Azar Poses Existential Threat to Medicare Outpatient Prospective Payment System (*Alerts/Updates*)
- 27 July 2020, President Trump Signs Drug Pricing Executive Orders Reinforcing the Administration's Priorities (*Alerts/Updates*)
- 23 July 2020, K&L Gates Triage: Recent Developments in the 340B Drug Pricing Program (*Podcast*)
- 21 July 2020, 340B Update: HRSA Indicates it Lacks Authority to Enforce 340B Program Guidance (*Alerts/Updates*)

OTHER PUBLICATIONS

- "Strategic Planning for Physician Practice Acquisitions in the Post-Site Neutrality Payment Era," *American Health Lawyers Association*
- Editor, "Price Transparency Rules," *American Health Lawyers Association*
- "60-Day Repayment Rule: Implications for Internal and External Audits," *American Health Lawyers Association*
- "60-Day Overpayment Rule Medicare Parts A and B," *American Health Lawyers Association*
- "Don't put the CAR-T before the Horse: Proper Planning for Novel Gene Therapies in an Uncertain Regulatory Environment," *American Health Lawyers Association*
- "Provider-Based Status, Under Arrangements, Enrollment and Related Medicare Requirements," *American Health Lawyers Association*
- "Provider-Based Status under Siege: Do the Benefits Justify the Costs of Compliance?" *American Health Lawyers Association*
- "What Every AMC Needs to Know about the 340B Program," *American Health Lawyers Association*

NEWS & EVENTS

- 7 July 2020, K&L Gates Continues Health Care Practice Growth with Washington, D.C., Partner Addition (*Press Release, Practice & Regional News*)

AREAS OF FOCUS

- Health Care and FDA
- Food, Drugs, Medical Devices, and Cosmetics (FDA)
- Health Care Fraud and Abuse (U.S.)
- Health Care Payor-Provider Disputes (U.S.)